Skip to main content
SpringerLink
Log in

Effects of Chronic Administration of Buspirone to Female Mice in Conditions of Prolonged Psychoemotional Stress

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Abstract

The effects of chronic administration (30 days) of the partial 5-HT1A receptor agonist buspirone (0.05, 1, and 10 mg/kg i.p.) on the behavior of female C57BL/6 J mice in conditions of prolonged psychoemotional stress were studied. Stress was produced by keeping females in a cage with an aggressive male on the other side of a perforated partition, along with the daily occurrence of 10-min intermale confrontations between the aggressor and another male placed with it. Chronic administration of buspirone at all the doses tested had no effect on the behavior of the females assessed in the partition and open field tests at the end of the treatment period. The elevated plus maze test showed that buspirone had anxiolytic effects, but only at a dose of 1 mg/kg. In the Porsolt test, buspirone (1 mg/kg) produced a minor increase in the duration of immobility, pointing to some antidepressant effect. Thus, chronic administration of buspirone to females in conditions of prolonged psychoemotional stress had different effects on their behavior depending on the dose and test conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. D. F. Avgustinovich, “Anxiety in females induced by psychoemotional stress,” Ros. Fiziol. Zh. im. I. M. Sechenova, 89, No. 7, 858–867 (2003).

    CAS  Google Scholar 

  2. D. F. Avgustinovich, G. B. Vishnivetskaya, and L. A. Koryakina, “Effects of acute and chronic administration of buspirone on communicativeness in mice with experience of social defeats,” Byull. Eksperim. Biol. Med., 149, No. 1, 64–68 (2010).

    Google Scholar 

  3. D. F. Avgustinovich and I. L. Kovalenko, “Formation of behavioral pathology in female C57BL/6 J mice exposed to prolonged psychoemotional stress,” Ros. Fiziol. Zh. im. I. M. Sechenova, 90, No. 11, 1324–1336 (2004).

    CAS  Google Scholar 

  4. D. F. Avgustinovich and I. L. Kovalenko, “Sexual characteristics of responses to prolonged psychoemotional stress in mice,” Ros. Fiziol. Zh. im. I. M. Sechenova, 95, No. 1, 65–73 (2009).

    CAS  Google Scholar 

  5. B. J. C. Allman, A. Domantay, and H. S. Schoeman, “Antidepressant activity of buspirone in anxiety,” Curr. Therapeut. Res., 52, No. 3, 406–411 (1992).

    Article  Google Scholar 

  6. D. F. Avgustinovich, O. V. Alekseyenko, and L. A. Koryakina, “Effects of chronic treatment with ipsapirone and buspirone on the C57BL/6 J strain mice under social stress,” Life Sci., 72, 1437–1444 (2003).

    Article  PubMed  CAS  Google Scholar 

  7. D. F. Avgustinovich, T. V. Lipina, N. P. Bondar, O. V. Alekseyenko, and N. N. Kudryavtseva, “Features of the genetically defined anxiety in mice,” Behav. Genet., 30, No. 2, 101–1019 (2000).

    Article  PubMed  CAS  Google Scholar 

  8. J. C. Ballenger, “Anxiety and depression: Optimizing treatments. Primary care companion,” J. Clin. Psychiatry, 2, No. 3, 71–79 (2000).

    Google Scholar 

  9. C. Belzung and G. Griebel, “Measuring normal and pathological anxiety-like behaviour in mice: a review,” Behav. Brain Res., 125, 141–149 (2001).

    Article  PubMed  CAS  Google Scholar 

  10. P. Blier and N. M. Ward, “Is there a role for 5-HT1A agonists in the treatment of depression?” Biol. Psychiatr., 53, No. 3, 193–203 (2003).

    Article  CAS  Google Scholar 

  11. F. Borsini and A. Meli, “Is the forced swimming test a suitable model for revealing antidepressant activity?” Psychopharmacology, 94, 147–160 (1988).

    Article  PubMed  CAS  Google Scholar 

  12. A. Briones-Aranda, C. López-Rubalcava, and O. Picazo, “Influence of forced swimming-induced stress on the anxiolytic-like effect of 5-HT1A agents in mice,” Psychopharmacology, 162, 147–155 (2002).

    Article  PubMed  CAS  Google Scholar 

  13. A. P. Carobrez and L. J. Bertoglio, “Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on,” Neurosci. Biobehav. Rev., 29, No. 8, 1193–1205 (2005).

    Article  PubMed  CAS  Google Scholar 

  14. E. Choleris, A. W. Thomas, M. Kavaliers, and F. S. Prato, “A detailed ethological analysis of the mouse open field test: effects of diazepam, chlordiazepoxide and an extremely low frequency pulsed magnetic field,” Neurosci. Biobehav. Rev., 25, 235–260 (2001).

    Article  PubMed  CAS  Google Scholar 

  15. A. Dalvi and I. Lucki, “Murine models of depression,” Psychopharmacology (Berlin), 147, No. 1, 14–16 (1999).

    Article  CAS  Google Scholar 

  16. J. A. Den Boer, F. J. Bosker, and B. R. Slaap, “Serotinergic drugs in the treatment of depression and anxiety disorders,” Hum. Psychopharmacol., 15, No. 5, 315–336 (2000).

    Article  Google Scholar 

  17. M. J. Detke, J. Johnson, and I. Lucki, “Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression,” Exp. Clin. Psychopharmacol., 5, No. 2, 107–112 (1997).

    Article  PubMed  CAS  Google Scholar 

  18. J. De Vry, T. Glaser, T. Schuurman, R. Schreiber, and J. Traber, “5-HT1A receptors in anxiety,” in: New Concepts in Anxiety, M. Briely (ed.), MacMillan Press, London (1991), pp. 94–129.

    Google Scholar 

  19. J. M. De Vry, R. Schreiber, T. Glaser, and J. Traber, “Behavioral pharmacology of 5-HT1A agonists: animal models of anxiety and depression,” in: Serotonin 1A Receptors in Depression and Anxiety, S. M. Stahl, M. Gastpar, J. M. Keppel, and J. Traber (eds.), Raven Press, New York (1992), pp. 55–81.

    Google Scholar 

  20. E. J. Frackiewicz, J. J. Sramek, and N. R. Cutler, “Gender differences in depression and antidepressant pharmacokinetics and adverse effects,” Ann. Pharmacother., 34, No. 1, 80–88 (2000).

    Article  PubMed  CAS  Google Scholar 

  21. J. M. Gorman, “Gender differences in depression and response to psychotropic medication,” Gend. Med., 3, No. 2, 93–109 (2006).

    Article  PubMed  Google Scholar 

  22. G. Griebel, “5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research,” Pharmacol. Ther., 65, No. 3, 319–395 (1995).

    Article  PubMed  CAS  Google Scholar 

  23. J. Haller, J. Baranyi, N. Bakos, and J. Halász, “Social instability in female rats: effects on anxiety and buspirone efficacy,” Psychopharmacology (Berlin), 174, No. 2, 197–202 (2004).

    Article  CAS  Google Scholar 

  24. N. N. Kudryavtseva, “Experience of defeats decreases the behavioral reactivity to conspecific in partition test,” Behav. Process., 32, 297–304 (1994).

    Article  Google Scholar 

  25. N. N. Kudryavtseva and D. F. Avgustinovich, “Behavioral and physiological markers of experimental depression induced by social conflicts (DISC),” Aggress. Behav., 24, 271–286 (1998).

    Article  Google Scholar 

  26. L. W. Lim, Y. Temel, T. Sesia, R. Vlamings, V. Visser-Vandewalle, H. W. Steinbusch, and A. Blokland, “Buspirone induced acute and chronic changes of neural activation in the periaqueductal gray of rats,” Neurosci., 155, No. 1, 164–173 (2008).

    Article  CAS  Google Scholar 

  27. C. López-Rubalcava, “Pre- or postsynaptic activity of 5-HT1A compounds in mice depends on the anxiety paradigm,” Pharmacol. Biochem. Behav., 54, No. 4, 677–686 (1996).

    Article  PubMed  Google Scholar 

  28. I. Lucki, A. Dalvi, and A. J. Mayorga, “Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice,” Psychopharmacology (Berlin), 155, No. 3, 315–322 (2001).

    Article  CAS  Google Scholar 

  29. E. Majercsik, J. Haller, C. Leveleki, J. Baranyi, J. Halász, and R. J. Rodgers, “The effect of social factors on the anxiolytic efficacy of buspirone in male rats, male mice, and men,” Prog. Neuropsychopharmacol. Biol. Psychiat., 27, No. 8, 1187–1199 (2003).

    Article  CAS  Google Scholar 

  30. W. T. McKinney and W. E. Bumney, “Animal model of depression. I. Review of evidence: implications for research,” Arch. Gen. Psychiat., 21, No. 2, 240–248 (1969).

    Article  PubMed  Google Scholar 

  31. M. J. Millan, “The neurobiology and control of the anxious state,” Prog. Neurobiol., 70, 83–244 (2003).

    Article  PubMed  CAS  Google Scholar 

  32. J. C. Nelson, “Augmentation strategies in depression 2000,” J. Clin. Psychiat., 61, Supplement 2, 13–19 (2000).

    Google Scholar 

  33. F. Ohl, “Testing for anxiety,” Clin. Neurosci. Res., 3, 233–238 (2003).

    Article  Google Scholar 

  34. J. C. Pecknold, P. Familamiri, H. Chang, R. Wilson, J. Alarcia, and D. J. McClure, “Buspirone: anxiolytic?” Prog. Neuropsychopharmacol. Biol. Psychiat., 9, No. 5–6, 639–642 (1985).

    Article  CAS  Google Scholar 

  35. M. Piccinelli and G. Wilkinson, “Gender differences in depression. Critical review,” Brit. J. Psychiat., 177, 486–492 (2000).

    Article  PubMed  CAS  Google Scholar 

  36. R. D. Porsolt, G. Anton, N. Blavet, and M. Jalfre, “Behavioral despair in rats: a new model of sensitivity to antidepressant treatments,” Eur. J. Pharmacol., 47, No. 4, 379–391 (1978).

    Article  PubMed  CAS  Google Scholar 

  37. R. D. Porsolt, A. Bertin, and M. Jalfre, “Behavioral despair in mice: a primary screening test for antidepressants,” Arch. Int. Pharmacodyn. Ther., 229, 327–336 (1977).

    PubMed  CAS  Google Scholar 

  38. L. Prut and C. Belzung, “The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review,” Eur. J. Pharmacol., 463, No. 1–3, 3–33 (2003).

    Article  PubMed  CAS  Google Scholar 

  39. A. Ramos and P. Mormede, “Stress and emotionality: a multidimensional and genetic approach,” Neurosci. Biobehav. Rev., 22, No. 1, 33–57 (1998).

    Article  PubMed  CAS  Google Scholar 

  40. D. S. Robinson, K. Rickels, J. Feighner, L. F. Fabre, R. E. Gammans, R. C. Shrotriya, D. R. Alms, J. J. Andary, and M. E. Messina, “Clinical effect of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression,” J. Clin. Psychopharmacol., 10, No. 3, Supplement, 67S–76S (1990).

    Article  PubMed  CAS  Google Scholar 

  41. S. Ros, L. Agüera, J. De la Gándara, J. E. Rojo, and J. M. De Pedro, “Potentiation strategies for treatment-resistant depression,” Acta Psychiat. Scand., 112, Supplement 428, 14–24 (2005).

    Article  Google Scholar 

  42. L. J. Sim-Selley, L. J. Vogt, R. Xiao, S. R. Childers, and D. E. Selley, “Region-specific changes in 5-HT1A receptor-activated G-proteins in rat brain following chronic buspirone,” Eur. J. Pharmacol., 389, No. 2–3, 147–153 (2000).

    Article  PubMed  CAS  Google Scholar 

  43. J. J. Sramek,V. Zarotsky, and N. R. Cutler, “Generalised anxiety disorder: treatment options,” Drugs, 62, No. 11, 1635–1648 (2002).

    Article  PubMed  CAS  Google Scholar 

  44. P. E. Stokes and A. Holtz, “Fluoxetine tenth anniversary update: the progress continues,” Clin. Ther., 19, No. 5, 1135–1250 (1997).

    Article  PubMed  CAS  Google Scholar 

  45. M. Tsuji, H. Takeda, and T. Matsumiya, “Different effects of 5-HT1A receptor agonists and benzodiazepine anxiolytics on the emotional state of naïve and stressed mice: a study using the hole-board test,” Psychopharmacology (Berlin), 152, No. 2, 157–166 (2000).

    Article  CAS  Google Scholar 

  46. J. B. Williams, R. L. Spitzer, M. Linzer, K. Kroenke, S. R. Hahn, F.V. deGruy, and A. Lazev, “Gender differences in depression in primary care,” Am. J. Obstet. Gynecol., 173, No. 2, 654–659 (1995).

    Article  PubMed  CAS  Google Scholar 

  47. H. Wong, R. C. Dockens, L. Pajor, S. Yeola, J. E. Grace, Jr., A. D. Stark, R. A. Taub, F. D. Yocca, R. C. Zaczek, and Y. W. Li, “6-Hydroxydopamine is a major active metabolite of buspirone: assessment of pharmacokinetics and 6-hydroxytryptamine 1A receptor occupancy in rats,” Drug. Metab. Disposition, 35, No. 8, 1387–1392 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, 10 Lavrentiev Prospekt, 630090, Novosibirsk, Russia

    D. F. Avgustinovich & G. B. Vishnivetskaya

Authors
  1. D. F. Avgustinovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. B. Vishnivetskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. F. Avgustinovich.

Additional information

Translated from Rossiiskii Fiziologicheskii Zhurnal imeni I. M. Sechenova, Vol. 97, No. 2, pp. 189–202, February, 2011.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Avgustinovich, D.F., Vishnivetskaya, G.B. Effects of Chronic Administration of Buspirone to Female Mice in Conditions of Prolonged Psychoemotional Stress. Neurosci Behav Physi 42, 634–642 (2012). https://doi.org/10.1007/s11055-012-9614-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-012-9614-y

Keywords

Search

Navigation